Buffeted by Weak Sales and Restructuring, Gene Logic Weighs Future of Genomics Unit | GenomeWeb
The future of Gene Logic’s genomics and toxicogenomics division hung in the balance last week as the company announced plans to lay off 80 of the unit’s employees and a 67-percent decline in second-quarter sales dragged down total revenue by nearly half.
The results couldn’t have been farther from what Gene Logic had planned for its genomics business this year when CFO Phil Rohrer said in February said that for 2006 it expected its genomics business to continue to grow.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.